^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OMO-103

    i
    Other names: OMO-103, Omomyc cell-penetrating peptide, OMO103
    Company:
    Peptomyc
    Drug class:
    MYC inhibitor
    Related drugs:
    25d
    Osteomyc: A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients with Advanced High-Grade Osteosarcoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Vall d'Hebron Institute of Oncology
    New P2 trial • Metastases
    |
    OMO-103
    7ms
    MYCure: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (clinicaltrials.gov)
    P1/2, N=22, Terminated, Peptomyc S.L. | Active, not recruiting --> Terminated; Phase 1completed; sponsor decided to change strategy to a combination study
    Trial termination • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • RAS mutation
    |
    OMO-103
    over1year
    Progress in the development of a clinically viable MYC inhibitor (EACR 2023)
    An Omomyc-based mini-protein therapeutic developed by Peptomyc S.L. – OMO-103 – has recently successfully completed a Phase 1 clinical study, demonstrating safety and clear signs of target engagement...ConclusionMYC inhibition is finally progressing through clinical trials and it is revealing new aspects of MYC biology, including in the context of immune modulation. The pleiotropic role of MYC in drug resistance and survival suggests that MYC inhibition could be useful to increase the efficacy of – and prevent resistance to – standard-of-care therapies.
    Clinical • PARP Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    OMO-103
    2years
    MYCure: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (clinicaltrials.gov)
    P1/2, N=22, Active, not recruiting, Peptomyc S.L. | Recruiting --> Active, not recruiting | N=74 --> 22
    Enrollment closed • Enrollment change • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • RAS mutation
    |
    OMO-103
    over3years
    MYCure: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (clinicaltrials.gov)
    P1/2, N=74, Recruiting, Peptomyc S.L. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    OMO-103
    over3years
    MYCure: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (clinicaltrials.gov)
    P1/2, N=74, Not yet recruiting, Peptomyc S.L.
    Clinical • New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    OMO-103